The estimated Net Worth of Francis Cano is at least $75.5 Thousand dollars as of 31 May 2024. Francis Cano owns over 3,615 units of Biomerica stock worth over $11,477 and over the last 15 years he sold BMRA stock worth over $64,067. In addition, he makes $0 as Independent Director at Biomerica.
Francis has made over 13 trades of the Biomerica stock since 2011, according to the Form 4 filled with the SEC. Most recently he sold 3,615 units of BMRA stock worth $43,127 on 31 May 2024.
The largest trade he's ever made was exercising 25,000 units of Biomerica stock on 26 October 2018 worth over $18,750. On average, Francis trades about 4,515 units every 123 days since 2009. As of 31 May 2024 he still owns at least 36,905 units of Biomerica stock.
You can see the complete history of Francis Cano stock trades at the bottom of the page.
Dr. Francis R. Cano Ph.D. serves as Independent Director of the Company. Dr. Cano is the managing director of Cano Biotechnology, a consulting business which is focused on vaccines and immunotherapeutics. He co-founded Aviron in 1993 and served as the President and Chief Operating Officer. The Company developed the intranasal flu vaccine, Flu-Mist, and was acquired by MedImmune in 2002 for $1.2 billion. From 1972-1993 Dr. Cano held various scientific/management positions with American Cyanamid, the last of which was as Vice President-General Manager of the Lederle-Praxis Biological Division. From fiscal 2001 through 2008, Dr. Cano also served on the board of Lancer Orthodontics, Inc., and currently serves on the board of Arbor Vita Corporation and Dynavax.
Francis Cano is 76, he's been the Independent Director of Biomerica since 1999. There are no older and 10 younger executives at Biomerica.
Francis's mailing address filed with the SEC is C/O DYNAVAX TECHNOLOGIES, 2100 POWELL STREET, SUITE 720, EMERYVILLE, CA, 94608.
Over the last 12 years, insiders at Biomerica have traded over $80,900 worth of Biomerica stock and bought 151,277 units worth $334,788 . The most active insiders traders include Mark A Sirgo, David Moatazedi, and John P. Kenny. On average, Biomerica executives and independent directors trade stock every 61 days with the average trade being worth of $3,349. The most recent stock trade was executed by Zackary S. Irani on 25 May 2023, trading 700 units of BMRA stock currently worth $1,113.
biomerica, inc. (www.biomerica.com) is a global biomedical company that develops, manufactures and markets advanced diagnostic products used at the point-of-care (in home and in physicians’ offices) and in hospital/clinical laboratories for the early detection of medical conditions and diseases. the company’s products are designed to enhance health and well-being, while reducing total healthcare costs. biomerica primarily focuses on products for gastrointestinal disease, diabetes and esoteric testing. the biomerica infoods® ibs product identifies patient specific foods that when removed may alleviate an individual's ibs symptoms. this patent pending diagnostic guided therapy is designed to allow for a patient specific guided dietary regimen to improve irritable bowel syndrome (ibs) outcomes. the point-of-care product is being developed to allow physicians to perform the test in-office using a finger stick blood sample while a clinical lab version of the product will be the first for wh
Biomerica executives and other stock owners filed with the SEC include: